HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Diphtheria-Tetanus-acellular Pertussis Vaccines (Tripedia)

Subscribe to New Research on Diphtheria-Tetanus-acellular Pertussis Vaccines

Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.

Also Known As:

Tripedia; ACEL-IMUNE; DTaP Vaccine; Infanrix; ACEL IMUNE; ACELIMUNE; Diphtheria Tetanus acellular Pertussis Vaccines; Pertussis Vaccines, Diphtheria-Tetanus-acellular; Vaccine, DTaP; Vaccines, DTaP; Vaccines, Diphtheria-Tetanus-acellular Pertussis; DTaP Vaccines

Networked: 206 relevant articles (13 outcomes, 43 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Centers for Disease Control and Prevention (CDC): 7 articles (10/2014 - 02/2002)
2.	Jackson, Lisa A: 7 articles (05/2014 - 08/2002)
3.	Nelson, Jennifer C: 6 articles (05/2014 - 03/2006)
4.	Geier, Mark R: 6 articles (01/2013 - 06/2003)
5.	Klein, Nicola P: 5 articles (05/2014 - 11/2008)
6.	Geier, David A: 5 articles (01/2013 - 06/2003)
7.	Halperin, Scott A: 5 articles (11/2009 - 12/2005)
8.	Pichichero, M E: 4 articles (12/2015 - 01/2000)
9.	Greenberg, David P: 4 articles (11/2014 - 04/2002)
10.	Nordin, James D: 4 articles (05/2014 - 03/2011)

Related Diseases

1.	Whooping Cough (Pertussis) 08/01/2005 - "Any combination of > or =3 DTP/DTaP vaccine doses for children 6 to 59 months of age was highly protective against pertussis. " 07/17/2015 - "Sweden introduced DTaP vaccines in 1996 after a 17-year hiatus with no general pertussis vaccination and pertussis was still endemic at the time of the studies. " 01/01/2015 - "Pertussis cases aged 2 months-1 year were 90% vaccinated following the current DTaP schedule for their age group in Catalonia, and cases of 5-9 years were 87% fully vaccinated with 5 doses of DTaP vaccine. " 06/01/2014 - "To understand the effect of vaccination in the era of acellular pertussis vaccines (DTaP and Tdap), we assessed if vaccination status is associated with disease severity and duration. " 11/01/2013 - "Undervaccination with DTaP vaccine increases the risk of pertussis among children 3 to 36 months of age."
2.	Diphtheria 07/01/2011 - "We provide an overview of 16 years of clinical experience with a diphtheria (D), tetanus (T), aP, IPV and Haemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus protein (PRP∼T) combined vaccine (DTaP-IPV//PRP∼T - Pentaxim, Sanofi Pasteur, France). " 03/01/2009 - "More recently, a refinement of this method based on dermal temperature measurement has been developed for ACVs in combination with diphtheria and tetanus vaccines (DTaP). " 01/01/1996 - "Tetanus antibody was higher pre- and post-vaccination for DTwP versus both DTaP vaccine groups, and diphtheria antibody was similar pre- and post-vaccination for all 3 groups. " 01/01/2005 - "Replacement of the diphtheria and aP components with these improved antigens will reduce the amount of protein in DTaP vaccine and, most likely, the incidence and severity of local reactions in teenagers and adults." 11/01/2014 - "Children who had received 5 previous doses of any diphtheria-tetanus-acellular pertussis (DTaP) vaccine were enrolled in a phase IV clinical trial; 646 10-year-olds and 645 11-year-olds completed the study, which involved a single intramuscular dose of Tdap5 along with pre- and postvaccination serologies. "
3.	Tetanus 07/01/2011 - "We provide an overview of 16 years of clinical experience with a diphtheria (D), tetanus (T), aP, IPV and Haemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus protein (PRP∼T) combined vaccine (DTaP-IPV//PRP∼T - Pentaxim, Sanofi Pasteur, France). " 03/01/2009 - "More recently, a refinement of this method based on dermal temperature measurement has been developed for ACVs in combination with diphtheria and tetanus vaccines (DTaP). " 01/01/1996 - "Tetanus antibody was higher pre- and post-vaccination for DTwP versus both DTaP vaccine groups, and diphtheria antibody was similar pre- and post-vaccination for all 3 groups. " 01/01/2013 - "HibT vaccine and HibT components of imported DTaP-HibT vaccine alone showed comparable or higher anti-tetanus potency than DTaP vaccine and DTaP-containing components of combination vaccines. " 01/01/1996 - "These 2- and 3-component DTaP vaccines produce less common reactions and comparable or higher antibody to the components they contain (except tetanus) than DTwP vaccine when given as a booster to 15- to 20-month-old children previously primed with the same vaccine."
4.	Infection 12/01/2014 - "While previous reports documented a mixed Th1/Th2 or Th2-skewed response to DTaP vaccine in children, our data suggest that following the first DTaP booster, children aged 16 to 19 months have a cytokine profile consistent with a Th1 response, which is known to be essential for clearance of pertussis infection. " 01/01/1998 - "In contrast with DTP, the DTaP vaccine had some efficacy against B parapertussis infection (point estimate for cough >/=7 days: 31% [95% CI: -10-56]). " 01/01/1998 - "Like other multicomponent acellular pertussis vaccines, the Lederle/Takeda DTaP vaccine demonstrated good efficacy against mild and typical pertussis due to B pertussis infections. " 06/04/1999 - "In a respiratory mouse model, a tricomponent acellular pertussis vaccine (Infanrix) was highly effective in promoting lung clearance of all isolates expressing different S1 subunit and pertactin suggesting that use of acellular vaccine will not increase the risks of pertussis infection by these B. " 11/01/2013 - "Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age."
5.	Cough 01/01/1998 - "For DTaP vaccine, efficacy was higher after the fourth dose as compared with its efficacy after the third dose (78% vs 62% for cough >/=7 days and 85% vs 76% for cough >/=21 days with PWV). " 10/01/1998 - "Using a clinical case definition that included both mild and typical pertussis (cough illness >/=7 days duration) efficacy of DTaP vaccine was 40% (95% confidence interval [CI] = -3-65) in the high compliance category and 78% (95% CI = 65-86) and 75% (95% CI = 53-87) in the intermediate and low compliance groups, respectively. " 01/01/1998 - "In contrast with DTP, the DTaP vaccine had some efficacy against B parapertussis infection (point estimate for cough >/=7 days: 31% [95% CI: -10-56]). " 10/01/1998 - "Using a clinical case definition that required >/=21 days of cough with paroxysms, whoop, or vomiting (typical pertussis) the efficacy of DTaP vaccine was 69% (95% CI = 41-83) in the high compliance category and 86% (95% CI = 76-92) and 84% (95% CI = 64-93) in the intermediate and low compliance groups, respectively. "

Related Drugs and Biologics

1.	Pertussis Vaccine
2.	Antigens
3.	pertactin
4.	Vaccines
5.	Toxoids
6.	pertussis toxoid
7.	Hemagglutinins (Hemagglutinin)
8.	Diphtheria-Tetanus-Pertussis Vaccine (DPT Vaccine)
9.	DNA (Deoxyribonucleic Acid)
10.	Tetanus Toxoid (Vaccine, Tetanus)

Related Therapies and Procedures

1.	Injections
2.	Highly Active Antiretroviral Therapy (HAART)
3.	Day Care (Partial Hospitalization)